CD8+ 肿瘤浸润淋巴细胞与 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌患者预后的相关性：系统评价和荟萃分析。

Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.

机构信息

Department of Thoracic Surgery, Jinan Central Hospital, Shandong University, Jinan, Shandong, China.

Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.

出版信息

Expert Rev Anticancer Ther. 2023 Jun;23(6):643-659. doi: 10.1080/14737140.2023.2208351. Epub 2023 May 4.

DOI:10.1080/14737140.2023.2208351

PMID:37114477

Abstract

BACKGROUND

A meta-analysis method was used to investigate the prognostic value of CD8+ tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.

METHODS

A database search of PubMed, Embase, Web of Science and Cochrane Library up until 7 February, 2023. A clinical study on the relationship between CD8+ TILs and PD-1/PD-L1 inhibitors in the therapeutics of NSCLC. RevMan 5.3 and StataMP 17.0 software were used for meta-analysis. The outcome indicators incorporated overall survival (OS), progression-free survival (PFS) and objective response rate (ORR).

RESULTS

Nineteen articles with 1488 patients were included. The analysis results showed that high CD8+ TILs were associated with better OS (HR = 0.60, 95% CI: 0.46-0.77; < 0.0001), PFS (HR = 0.68, 95% CI: 0.53-0.88; = 0.003) and ORR (OR = 2.26, 95% CI: 1.52-3.36; < 0.0001) in NSCLC patients treated with PD-1/PD-L1 inhibitors. Subgroup analysis indicated that patients with high CD8+ TILs had good clinical prognostic benefits whether the location of CD8+ TILs was intratumoral or stromal, and compared with East Asian, high CD8+ TILs in Caucasians showed a better prognosis. High CD8+ TILs in peripheral blood did not improve OS (HR = 0.83, 95% CI: 0.69-1.01; = 0.06) and PFS (HR = 0.93, 95% CI: 0.61-1.14; = 0.76) in NSCLC patients receiving PD-1/PD-L1 inhibitors.

CONCLUSION

In spite of the location of CD8+ TILs, high densities of CD8+ TILs were predictive of treatment outcomes in NSCLC patients treated with PD-1/PD-L1 inhibitors. However, high CD8+ TILs in peripheral blood had no predictive effect.

摘要

背景

采用荟萃分析方法研究 CD8+肿瘤浸润淋巴细胞（TILs）在接受 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌（NSCLC）患者中的预后价值。

方法

检索 PubMed、Embase、Web of Science 和 Cochrane Library 数据库，检索时间截至 2023 年 2 月 7 日。临床研究评估了 CD8+TILs 与 PD-1/PD-L1 抑制剂在 NSCLC 治疗中的相关性。采用 RevMan 5.3 和 StataMP 17.0 软件进行荟萃分析。结局指标包括总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。

结果

纳入 19 项研究共 1488 例患者。分析结果显示，高 CD8+TILs 与 NSCLC 患者接受 PD-1/PD-L1 抑制剂治疗后的 OS（HR=0.60，95%CI：0.46-0.77；<0.0001）、PFS（HR=0.68，95%CI：0.53-0.88；=0.003）和 ORR（OR=2.26，95%CI：1.52-3.36；<0.0001）改善相关。亚组分析表明，无论 CD8+TILs 的位置是肿瘤内还是间质内，高 CD8+TILs 患者均具有良好的临床预后获益，与东亚相比，高加索人群中高 CD8+TILs 患者的预后更好。外周血中高 CD8+TILs 并不能改善 NSCLC 患者接受 PD-1/PD-L1 抑制剂治疗后的 OS（HR=0.83，95%CI：0.69-1.01；=0.06）和 PFS（HR=0.93，95%CI：0.61-1.14；=0.76）。